

# Donald C Moore

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/301281/publications.pdf>

Version: 2024-02-01

34  
papers

197  
citations

1163117

8  
h-index

1199594

12  
g-index

34  
all docs

34  
docs citations

34  
times ranked

220  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas. <i>Annals of Pharmacotherapy</i> , 2020, 54, 371-379.	1.9	21
2	Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e777-e781.	0.4	15
3	Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 1201-1207.	1.0	15
4	Case Report of Ipilimumab-Induced Diffuse, Nonnecrotizing Granulomatous Lymphadenitis and Granulomatous Vasculitis. <i>Journal of Pharmacy Practice</i> , 2018, 31, 227-229.	1.0	13
5	Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 431-440.	2.1	12
6	Fostamatinib for the treatment of immune thrombocytopenia in adults. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 789-794.	1.0	11
7	Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 470-475.	0.4	11
8	Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis. <i>Therapeutic Advances in Drug Safety</i> , 2020, 11, 204209862091505.	2.4	9
9	Case series of docetaxel-induced dorsal hand-foot syndrome. <i>Therapeutic Advances in Drug Safety</i> , 2018, 9, 495-498.	2.4	8
10	Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations. <i>Annals of Pharmacotherapy</i> , 2022, 56, 927-940.	1.9	8
11	Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses. <i>Leukemia and Lymphoma</i> , 2019, 60, 2295-2298.	1.3	6
12	Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 168-173.	0.4	6
13	Transitioning historically inpatient chemotherapy regimens for hematologic malignancies to the ambulatory care setting. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1824-1830.	1.0	5
14	Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 613-622.	0.9	5
15	Retrospective Analysis of Clinical Outcomes Associated With the Use of Pegfilgrastim On-body Injector in Patients Receiving Chemotherapy Requiring Granulocyte Colony-Stimulating Factor Support. <i>Hospital Pharmacy</i> , 2021, 56, 77-80.	1.0	5
16	Eptacog Beta for Bleeding Treatment and Prevention in Congenital Hemophilia A and B With Inhibitors: A Review of Clinical Data and Implications for Clinical Practice. <i>Annals of Pharmacotherapy</i> , 2022, 56, 831-838.	1.9	5
17	Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 49-54.	0.9	5
18	New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1848-1858.	0.9	5

#	ARTICLE	IF	CITATIONS
19	Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer. <i>Journal of Pharmacy Practice</i> , 2019, 32, 219-224.	1.0	4
20	Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e395-e398.	0.4	4
21	A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies. <i>Journal of the Advanced Practitioner in Oncology</i> , 2021, 12, 439-447.	0.4	4
22	Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type. <i>British Journal of Haematology</i> , 2022, 196, .	2.5	4
23	Acneiform Rash With Ramucirumab and Paclitaxel in a Patient With Recurrent Esophageal Cancer. <i>American Journal of Therapeutics</i> , 2018, 25, e557-e558.	0.9	2
24	Neutropenia-Associated Outcomes in Patients With Breast Cancer Receiving Myelosuppressive Chemotherapy With Reduced Doses of Pegfilgrastim. <i>Journal of Pharmacy Practice</i> , 2020, 33, 779-783.	1.0	2
25	Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma. <i>Annals of Hematology</i> , 2021, 100, 3053-3055.	1.8	2
26	Comparative Utilization and Efficacy of Thrombopoietin Receptor Agonists in Relapsed/Refractory Immune Thrombocytopenia. <i>American Journal of Therapeutics</i> , 2021, 28, e525-e530.	0.9	2
27	Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1993-1999.	0.9	2
28	Evaluation of a pharmacist-driven rapid infusion rituximab conversion protocol at a multisite cancer center. <i>Journal of Oncology Pharmacy Practice</i> , 2020, , 107815522097789.	0.9	2
29	Publication rates of hematology/oncology abstracts presented at major pharmacy association meetings. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 582-587.	0.9	1
30	New and emerging pharmacotherapies for management of multiple myeloma. <i>American Journal of Health-System Pharmacy</i> , 2022, , .	1.0	1
31	Brentuximab vedotin-induced pancreatitis in lymphoma: a pharmacovigilance study. <i>Leukemia and Lymphoma</i> , 2022, 63, 1768-1769.	1.3	1
32	Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 239-241.	0.9	1
33	Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 27, 107815522096744.	0.9	0
34	Implementation, utilization, and evaluation of a pharmacist-driven romiplostim dosing service for patients with immune thrombocytopenia at a multisite cancer centre. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 613-617.	0.9	0